Table 2.
Demographic data of patients enrolled in the study
| AR Group (n=39) |
Non-AR Group (n=101) |
p value | |
|---|---|---|---|
| Recipient Sex | |||
| Males | 23 (59%) | 65 (64.6%) | 0.55 |
| Females | 16 (41%) | 36 (35.6%) | |
| Recipient age | 37.0±2.4 | 36.5±1.8 | 0.94 |
| Donor Sex | |||
| Males | 18 (46%) | 29 (28.7%) | 0.27 |
| Females | 4 (10%) | 13 (12.9%) | |
| Donor age | 36.9±3.0 | 27.1±2.6 | 0.85 |
| Blood group | |||
| A | 17 (44%) | 28 (27.8%) | 0.711 |
| B | 6 (15%) | 14 (13.9%) | |
| AB | 2 (5%) | 7 (6.9%) | |
| O | 14 (36%) | 24 (23.8%) | |
| MELD score | 20.5±0.8 | 21.9±1.0 | 0.94 |
| Banff grade | |||
| Mild | 31 (79%) | ||
| Moderate | 6 (16%) | ||
| Severe | 2 (5%) | ||
| Immunosuppressive drugs | |||
| Tacrolimus dose | 4.25±2.43 | 2.34±1.24 | 0.08 |
| Cellcept dose | 2.88±1.14 | 1.17±1.56 | 0.09 |